Sugi Predict

Sugi Predict / Compounds / SCHEMBL2087006

SCHEMBL2087006

SCHEMBL2087006

CC(C)(C)[Si](C)(C)Oc1ccc(CCl)cc1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PREP P48147 4/20 0.45
▸ CA1 P00915 5/20 0.41
▸ CA12 O43570 4/20 0.41
▸ CA9 Q16790 4/20 0.41
▸ CASP3 P42574 2/20 0.33
▸ CASP7 P55210 2/20 0.33
▸ ADRB3 P13945 1/20 0.31
▸ DRD2 P14416 1/20 0.31
▸ ELANE P08246 1/20 0.31
▸ ALOX5AP P20292 1/20 0.31
▸ FEN1 P39748 1/20 0.31
▸ IDO1 P14902 1/20 0.31
▸ AGXT P21549 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ TTR P02766 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2507086 0.98 PREP (0.44) PREPCA1CA12CA9CASP3
SCHEMBL2997961 0.95 PREP (0.42) PREPCA1CA12CA9CASP3
SCHEMBL5973292 0.86 PREP (0.37) PREPCA1CA12CA9CASP3
SCHEMBL6763899 0.83 PREP (0.53) PREPCA1CA12CA9ALOX5AP
SCHEMBL12426281 0.82 PREP (0.46) PREPCA1CA12CA9
SCHEMBL1601708 0.82 PREP (0.46) PREPCA1CA12CA9CASP3
SCHEMBL318210 0.81 PPARA (0.47) PREPCA1CA12CA9DRD2
SCHEMBL14384880 0.81 PREP (0.45) PREPCA1CA12CA9CASP3
SCHEMBL4676713 0.81 IDO1 (0.50) PREPCA1CA12CA9CASP3
SCHEMBL6760799 0.81 PREP (0.45) PREPCA1CA12CA9CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239803-A1 SYNTHESIS OF COELENTERAZINE INTERNATIONAL PAPER COMPANY 2024-07-18 — — US claimed
US-11939332-B2 Synthesis of coelenterazine INTERNATIONAL PAPER COMPANY (US) 2024-03-26 — — US claimed
EP-3830088-A1 SYNTHESIS OF COELENTERAZINE International Paper Company (US) 2021-06-09 — — EP claimed
US-20210070762-A1 SYNTHESIS OF COELENTERAZINE INTERNATIONAL PAPER COMPANY (US) 2021-03-11 — — US claimed
US-20240239803-A1 SYNTHESIS OF COELENTERAZINE INTERNATIONAL PAPER COMPANY 2024-07-18 — — US disclosed
US-20240239803-A1 SYNTHESIS OF COELENTERAZINE INTERNATIONAL PAPER COMPANY 2024-07-18 — — US disclosed
US-20240239803-A1 SYNTHESIS OF COELENTERAZINE INTERNATIONAL PAPER COMPANY 2024-07-18 — — US disclosed
EP-4344689-A2 SYNTHESIS OF COELENTERAZINE International Paper Company (US) 2024-04-03 — — EP disclosed
US-11939332-B2 Synthesis of coelenterazine INTERNATIONAL PAPER COMPANY (US) 2024-03-26 — — US disclosed
US-11926624-B2 Synthesis of coelenterazine synthesis intermediate INTERNATIONAL PAPER COMPANY (US) 2024-03-12 — — US disclosed
CN-114080390-A Synthesis of coelenterazine 国际纸业公司 2022-02-22 — — CN disclosed
US-20210332044-A1 SYNTHESIS OF COELENTERAZINE SYNTHESIS INTERMEDIATE INTERNATIONAL PAPER COMPANY (US) 2021-10-28 — — US disclosed
US-7122679-B2 Multicyclic compounds and the use thereof CEPHALON, INC. (US) 2006-10-17 — — US disclosed
EP-1294725-B1 MULTICYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES CEPHALON INC (US) 2006-01-04 — — EP disclosed
US-6762205-B1 STEROID SULFATASE INHIBITORS WITHOUT ESTROGENIC SIDE EFFECT ACTION TEIKOKU HORMONE MFG. CO., LTD. (JP) 2004-07-13 — — US disclosed
EP-1294725-A2 MULTICYCLIC COMPOUNDS AND THE USE THEREOF AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES CEPHALON, INC. (US) 2003-03-26 — — EP disclosed
EP-1193250-A1 PHENYL SULFAMATE DERIVATIVES Teikoku Hormone Mfg. Co., Ltd. (JP) 2002-04-03 — — EP disclosed
US-20020028815-A1 Novel multicyclic compounds and the use thereof CEPHALON, INC. 2002-03-07 — — US disclosed
WO-2001085686-A2 MULTICYCLIC COMPOUNDS AND THE USE AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES CEPHALON, INC. (US) 2001-11-15 — — WO disclosed
EP-0438873-A1 Inhibitor of ribonucleotide reductase of herpes viruses MERCK & CO. INC. (US) 1991-07-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939332-B2 Synthesis of coelenterazine ACHE, UROD, DDT PREP 133/4885CA1 1411/4885CA12 1056/4885
US-20020028815-A1 Novel multicyclic compounds and the use thereof MLKL, PARP3, PARP1 PREP 1606/4885CA1 3731/4885CA12 4147/4885
US-20240239803-A1 SYNTHESIS OF COELENTERAZINE ACHE, UROD, DDT PREP 133/4885CA1 1411/4885CA12 1056/4885
US-20210070762-A1 SYNTHESIS OF COELENTERAZINE ACHE, UROD, DDT PREP 133/4885CA1 1411/4885CA12 1056/4885
US-11926624-B2 Synthesis of coelenterazine synthesis intermediate DCXR, SI, UROD PREP 144/4885CA1 1540/4885CA12 1248/4885
US-20210332044-A1 SYNTHESIS OF COELENTERAZINE SYNTHESIS INTERMEDIATE DCXR, SI, UROD PREP 144/4885CA1 1540/4885CA12 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.